JS Disrupt Battlefield 2023 Winner, BioticsAI, Receives FDA Clearance for AI Software Detecting Fetal Abnormalities
After claiming victory at the JS Disrupt Battlefield 2023, BioticsAI made a groundbreaking announcement on Monday regarding FDA clearance for their innovative AI software designed to detect fetal abnormalities in ultrasound images.
Founder and CEO Robhy Bustami, who comes from a family of obstetricians, drew inspiration from his upbringing and experiences in hospitals alongside his mother, aunt, and uncle. With a background in computer science from UC Irvine, Bustami partnered with Salman Khan, Chaskin Saroff, and Dr. Hisham Elgammal in 2021 to establish BioticsAI.
The AI technology developed by BioticsAI utilizes computer vision to enhance fetal ultrasound quality assessment, anatomical completeness, automated reporting, and seamless integration into clinical workflows. Bustami envisions that this technology will play a crucial role in addressing the concerning prenatal outcomes in the U.S., particularly among Black women who face a disproportionately high rate of maternal deaths.
Recognizing the pivotal role of prenatal ultrasound in monitoring pregnancies, Bustami emphasized the significance of addressing the challenges associated with low-quality images that can lead to misdiagnosis. Training their AI models on a diverse set of hundreds of thousands of ultrasounds, the team at BioticsAI focused on ensuring the reliability of their technology in real-world scenarios, especially among demographics with elevated risks.
Techcrunch Event
San Francisco
|
October 13-15, 2026
Following a rigorous process that spanned nearly three years, including FDA testing and validation, Bustami highlighted the importance of alignment between engineering, product development, clinical validation, and regulatory efforts from the outset. By integrating these aspects cohesively, rather than sequentially, BioticsAI was able to expedite their progress through the FDA clearance process.
With FDA approval secured, BioticsAI is now shifting its focus towards scaling their technology across various health systems nationwide. Additionally, plans are in place to introduce additional features catering to fetal medicine and reproductive health, further enhancing the impact and versatility of their product.
As Bustami looks ahead, he envisions a future where BioticsAI not only expands its distribution and clinical reach but also continues to enhance the capabilities of its technology. The journey towards revolutionizing prenatal care and improving maternal outcomes remains at the forefront of BioticsAI’s mission.
This piece was updated to correct the spelling of the co-founder’s name.
